Simulations Plus

Phase A — Understand the business

Lens 1 · Company Overview

Simulations Plus is a model-informed drug development (MIDD) / biosimulation company: it sells scientific software and consulting that lets pharma, biotech, agrochem, cosmetics and food companies simulate a drug's behavior in the body instead of (or before) running the wet-lab or animal experiment. Incorporated in California in July 1996; common stock on Nasdaq Global Select as SLP since 13 May 2021. HQ relocated from Lancaster, CA to Research Triangle Park, NC, with a European office in Paris, France (the Lixoft/MonolixSuite heritage).

How it makes money — two reportable segments (reorganized from nine reporting units to two in Q4 FY25):

• Software (58% of FY25 revenue, $45.8M, 79% gross margin): perpetual/term licenses for mechanistic simulators. Flagship GastroPlus (PBPK — predicts oral drug absorption/PK), ADMET Predictor (AI/ML property prediction in discovery), MonolixSuite (population PK/PD modeling), plus a stable of *sym disease models (DILIsym for liver injury, NAFLDsym, RENAsym, OBESITYsym, etc.) and Pro-ficiency (clinical-trial training).
• Services (42%, $33.4M, 30% gross margin): consulting by its PhD scientists — PKPD, QSP/QST, PBPK modeling, regulatory strategy, and Medical Communications (KOL work, also from Pro-ficiency).

Customers / contract structure: major pharma + biotech + regulators worldwide; software is fixed-price, net-30, generally annual licenses (low post-sale support cost — high incremental margin); services are project-based with a backlog. The company designates itself a CRO for the Pro-ficiency/clinical-ops business, which adds professional-liability exposure (Lens 10). Geography FY25: Americas $57.7M (73%), EMEA $14.2M (18%), Asia-Pacific $7.3M (9%).

The "ai-bio" hook is real but narrow: ADMET Predictor and the new "cloud-enabled modeling ecosystem" use AI/ML for property prediction and workflow automation, and the regulatory tailwind is the actual thesis — the FDA's April-2025 Roadmap to reduce animal testing explicitly names in silico PBPK modeling as a validated New Approach Methodology (NAM); SLP publicly endorsed it. This is not an LLM story; it's mechanistic physics-based simulation that regulators increasingly accept in lieu of animals.

Lens 2 · Supply Chain

A software/IP business has a thin physical chain, but the value chain has named, concentrable nodes:

• Upstream inputs: (1) scientific talent — PhD pharmacometricians/modelers are the raw material; the moat and the cost base are the same people. (2) Cloud infra — single-source on AWS ("We currently use AWS…") — a genuine single-vendor dependency for the cloud-delivered ecosystem. (3) Acquired technology — GastroPlus, Monolix (ex-Lixoft, Paris), DILIsym (ex-DILIsym Services), Pro-ficiency — the product line is a roll-up of acquired engines, so "supply" of new capability has historically been M&A, not pure R&D.
• The company itself: validated mechanistic engines + consulting scientists.
• End customers (the demand side, where concentration risk lives): branded pharma, generics, biotech, agrochem/cosmetics, and regulators themselves — the FDA, NIEHS, PAS, SACF are named partners. The FDA relationship is double-edged: it's a credibility moat and it means the demand thesis is partly a policy bet.
• Channel: ~$7.7M of FY25 software sold through representatives/distributors (notably in Japan/Asia).

Chokepoints: AWS single-source; talent retention post-10%-RIF (Lens 9); and — uniquely for this name — the regulatory acceptance pipeline (if the FDA NAM roadmap stalls, the structural demand pull weakens). No physical bottleneck, but the human and policy chokepoints are real.

Lens 3 · Competitive Advantages (moats)

The moat is regulatory-grade validation + switching costs, and it is real but eroding at the edges.

• Validation / regulatory credibility (strong): GastroPlus and the PBPK engines are cited in regulatory submissions; the FDA itself is a partner and PBPK is now named in the animal-testing roadmap. A pharma sponsor that has built its regulatory dossier on GastroPlus does not casually switch — the validation history is the lock-in.
• Switching costs (moderate-strong on software, weak on services): trained modelers, validated workflows, historical model libraries. Services are far more contestable.
• IP / installed base (moderate): decades of mechanistic model development; but the engines are mature — GastroPlus revenue is essentially flat ($20.8M→$21.8M→$22.1M over FY23-25, +1.2% in FY25), which says the core moat protects the base but no longer grows it.
• Bargaining power: strong over small-biotech customers (they need the validation more than SLP needs any one of them — no disclosed >10% customer concentration); weak vs. AWS (single-source) and weak vs. its own scientific labor.
• The competitive threat is named and larger: Certara (CERT). Certara is the scaled biosimulation leader (~$419M TTM revenue vs SLP's $79M) and explicitly positions as "the market leader in AI-enabled biosimulation and MIDD"; it launched a "Non-Animal Navigator" product directly into the same FDA-roadmap tailwind. SLP is the #2 pure-play at ~1/5 the scale — a real moat on its installed PBPK base, but not the category king.

Lens 4 · Segments

All figures `` (FY ends Aug-31; $000s).

By segment:

By product (the real story):

What the segment data reveals (decelerating, mix-deteriorating):

1. Total growth is now low-teens and almost entirely acquired — FY25's +$9.2M revenue was +$11.7M of full-year Pro-ficiency minus organic shrinkage elsewhere; management states the increase was "attributable to twelve months of revenue from the Pro-ficiency acquisition". Organic growth is roughly flat-to-down.
2. The flagship has plateaued. GastroPlus (~28% of total, ~48% of software) grew +1.2%. The crown jewel is ex-growth.
3. Margin mix is deteriorating. Software GM fell 90%→84%→79% (Pro-ficiency dev-tech amortization + lower-margin software acquired). Services GM collapsed 65%→30% — partly a FY24 reorg reclassification (services personnel moved into COGS) but also genuine pass-through-cost dilution.
4. Two service lines (QSP/QST −26%, PBPK −14%) are actively shrinking — the consulting demand softness that has hit the whole sector (cf. Certara guiding 0-4% growth for 2026 ).

This is the fundamental picture that broke the stock and, ultimately, drove the take-private.

---

Phase B — Measure performance

Lens 5 · Earnings Result (latest print: Q2 FY26, ended 28-Feb-2026)

Operationally a clean beat; the headline was a guidance trim and then, weeks later, a sale.

• Revenue $24.3M, +8% YoY (vs $22.4M) — beat consensus by ~12%. Software +9%, Services +8%.
• GAAP net income $4.535M (vs $3.074M PY); reported EPS $0.35 vs $0.27 expected; adj. EBITDA $8.7M (36% margin vs 29%).
• Gross margin 66% (vs 59%) — Software GM 89%, Services GM 33%, both up sharply, helped by lower amortization after the Pro-ficiency impairment and the May-2025 headcount cut. (Note: the margin "improvement" is partly the silver lining of having written the acquisition off.)
• R&D +46% to $4.3M (14% of revenue) — reinvesting into the "integrated, cloud-enabled modeling ecosystem… AI-driven capabilities".
• Guidance: FY26 revenue $79–82M unchanged; adj. diluted EPS cut from $1.03–1.10 to $0.75–0.85 — explicitly a tax-rate cut (effective rate 23-25% vs 12-14%, GILTI/FDII/jurisdictional mix), not an operational cut.
• Balance-sheet flags (FY25 10-K): cash + equivalents $30.9M, ST investments $1.5M, net working capital $44.8M, no debt. Operating cash flow $18.1M FY25 (vs $13.3M). Goodwill $43.7M (down from $96.1M after impairment); intangibles ~$18M still carried — residual impairment risk had it stayed public. Total assets $131.9M (from $196.6M).
• The FY25 result itself was ugly: revenue +13% to $79.2M but a $77.2M goodwill/intangible impairment ($37.1M Software RU + $40.1M Services RU; of which $72.2M was Pro-ficiency and $3.9M Immunetrics) drove a GAAP net loss of $(64.7)M and a $(70.7)M operating loss. Ex-impairment, operating income was ~$6.5M — i.e. the core was still modestly profitable; the loss was the admission that the $100M Pro-ficiency deal was a mistake.
• Market reaction / what was priced: the stock fell ~38% over the trailing year to ~$16.37 — the market had fully de-rated the name on broken-deal + decelerating-organic before Altaris bid $18.50 (a 26% premium to the 60-day VWAP, but still below where SLP traded for most of 2021-2024).

Lens 6 · Earnings Calls (sentiment trend)

No transcripts on the research shelf (transcripts=0); read from web coverage.

• Tone has shifted from "premium compounder" to "stabilize-and-reposition." Across the last several calls the language moved from acquisition-fuelled growth (Pro-ficiency "tremendous growth opportunity," FY24) to efficiency, margin, backlog, and "future growth" via the cloud/AI ecosystem (Q2 FY26: strong bookings, ~18% increase in services backlog, margin expansion).
• What they stopped saying: the bullish Pro-ficiency cross-sell narrative — replaced by impairment, restructuring, and a 10% RIF. What they started saying: "integrated platform," "AI-driven," "operating efficiency," "billable utilization."
• The final tonal shift is the sale itself — a board that two years earlier was buying growth at $100M is now selling the whole company at $375M. That is a capitulation signal as much as a transaction.

Lens 7 · Comps

Biosimulation/MIDD peer set. Multiples are `` with date or n/a. The category has de-rated together — both pure-plays trade like ex-growth software.

Read: SLP is being taken out at ~4.7x sales / a 26% premium, above Certara's ~2.3x EV/Sales multiple — consistent with (a) a control premium and (b) SLP's higher software mix / margin. But neither pure-play commands a growth multiple anymore; the whole "biosimulation rerates as AI-bio" thesis has, for now, failed in the public market. The Altaris bid is the market clearing the equity at a private-equity LBO-able level, not a strategic-scarcity price.

Lens 8 · Stock-Price Catalysts (>5% moves, ~5yr)

Mostly `` / inferred from filings.

• May 2021: uplisted to Nasdaq Global Select; rode the 2020-21 biotech/SaaS bubble to peak valuation (traded at premium SaaS multiples).
• 2022-23: sector de-rate as rate hikes compressed unprofitable/expensive SaaS and biotech R&D budgets tightened.
• Jun 2024: announced $100M+ Pro-ficiency acquisition — initially framed as growth-accretive.
• ~May–Jul 2025: the unwind — 10% RIF (2025 Restructuring), reorganization to 2 segments, and the $77.2M impairment (triggering event flagged 31-May-2025: revenue underperformance vs purchase-price forecasts + significant relative stock-price decline). Stock −38% over the trailing year.
• Apr 2026 (Q2 FY26): beat on revenue/EPS but cut adj-EPS guidance (tax) → muted-to-negative.
• ~16 Jun 2026: Altaris take-private at $18.50/share announced — the terminal catalyst; stock converges to deal price.

Pattern: SLP trades on (1) M&A (its own deals, now its own sale), (2) guidance/impairment credibility, and (3) sector-wide biosimulation/SaaS sentiment — not on individual product launches. The market reacts most violently when management's capital-allocation story is falsified (Pro-ficiency). That is the through-line.

---

Phase C — Judge people & books

Lens 9 · Management

• CEO: Shawn O'Connor — CEO since June 2018 (succeeded founder Walter Woltosz). CFO: Will Frederick (EVP & CFO; amended employment agreement Nov-2023). (No verified post-2025 CEO successor surfaced in search — treat any "new CEO" claim as unconfirmed; tenure read as O'Connor through the sale.)
• Founders still anchor the cap table: Walter & Virginia Woltosz own ~16% and signed the Voting & Support Agreement for the Altaris deal — meaningful remaining skin in the game and the reason the deal vote is near-locked.
• Capital-allocation track record — the central indictment: the Pro-ficiency acquisition ($100.2M, Jun-2024) was a value-destroying deal — ~$76M goodwill of which $72.2M was impaired within ~12 months, plus the smaller Immunetrics ($15.3M, 2023) whose second earnout was written to zero and which took a $3.9M impairment. Management bought growth at the top and wrote most of it off at the bottom. They also discontinued the dividend in FY2024 ("use those funds to invest more into our business") — and then the "invested" capital (Pro-ficiency) was impaired. That is a hard, quantified capital-allocation miss.
• Mitigants: the core business stayed cash-generative through the storm ($18.1M OCF FY25), the balance sheet stayed debt-free, and management executed a disciplined cost reset (10% RIF, margin recovery to 66% by Q2 FY26). They cleaned up reasonably after the mistake.
• Archetype: professional-manager-led, founder-anchored. O'Connor is a professional operator; the Woltoszes are the founder ballast. The implication: the board's willingness to sell (rather than defend a standalone turnaround) is consistent with a non-founder CEO + founders who'd rather crystallize $18.50 than ride the rebuild.

Lens 10 · Forensic Red Flags

Forensic-analyst lens. Every figure `` unless noted.

• Goodwill / intangibles — the headline forensic event already happened. $77.2M impairment in FY25 is the system working late: the company paid $100M for Pro-ficiency in Jun-2024 and impaired $72.2M of it by May-2025. Residual risk: $43.7M goodwill + ~$18M intangibles still carried post-impairment — for a company whose organic growth is flat, that book value was still aggressive (now resolved by the cash take-out at $18.50).
• Capitalized software development costs: $3.0M/$3.3M/$3.3M capitalized FY25/24/23 vs amortization $3.1M/$2.1M/$1.5M. Capitalization roughly matches amortization — not an earnings-flattering build; reasonable.
• Revenue recognition: ASC 606, fixed-price contracts, "significant judgment in estimation of hours/cost on consulting contracts" — the services side carries percent-complete estimation risk, but software (the majority) is point-in-time license recognition with low post-sale obligation. No revenue-rec red flag.
• Non-GAAP / SBC: the gap between $0.75-0.85 adjusted EPS and the GAAP loss is dominated by the (real, non-recurring) impairment and amortization of acquired intangibles — defensible adjustments, but a reminder that the adjusted numbers exclude the consequences of the company's own M&A.
• Cash vs earnings: OCF $18.1M FY25 exceeded GAAP results (because the loss was non-cash impairment) — cash quality is good, the divergence is the favorable direction. No receivables/inventory blow-out (it's a software/services model; AR is modest, no inventory).
• Tax: FY25 7% effective rate (impairment permanent-difference benefit), Q2 FY26 23% — the guidance cut is a tax-rate normalization, an honest disclosure, not a manipulation.

Regulatory findings (required):

• SEC: No Litigation Releases and no AAERs naming Simulations Plus, 2021-06-20 → 2026-06-20, verified via SEC EDGAR EFTS (LR + AAER).
• 10-K Item 3 (Legal Proceedings): Item 3 is present (TOC p.30); no material litigation is flagged in the filing beyond ordinary-course exposure. As a self-designated CRO, the company discloses professional-liability risk (errors/omissions in study reporting) as a risk factor, not an active proceeding.
• Non-SEC / deal-related: several plaintiff firms have announced "investigations" of the Altaris merger (fairness of the $18.50 price / disclosure adequacy) — these are routine, near-automatic for any public-company take-private and are not enforcement actions. No FTC/DOJ/FDA/CFPB enforcement found.
• Verdict: No material regulatory or accounting enforcement findings. The forensic story is a capital-allocation failure (a real impairment), fully disclosed — not fraud or a control breakdown.

---

Phase D — Project & stress-test

Lens 11 · Forward Projection

The standalone EPS path is now largely academic — the equity is a fixed-claim on $18.50 cash, not on FY27-29 earnings. I therefore frame this as (a) standalone, lightly, and (b) the deal arithmetic, which is what actually matters.

(a) Standalone (for reference only) — bottom-up from FY26 guidance, all ``:

• FY26 (guided): revenue $79-82M, adj diluted EPS $0.75-0.85.
• Base FY27: revenue ~$84M; adj EPS ~$0.90.
• Bull FY27: revenue ~$88M (+10%, FDA-NAM demand pull accelerates GastroPlus/PBPK), adj EPS ~$1.05.
• Bear FY27: revenue ~$80M (flat — services keep shrinking, pharma budgets stay tight), adj EPS ~$0.78.
• FY28-29: a 5-10% software-led grower with mid-single-digit services — if the AI/cloud ecosystem reignites GastroPlus and the FDA roadmap converts to bookings. The FY25 results say that re-acceleration is unproven.

(b) The deal arithmetic (what matters):

• Take-out: $18.50/share cash, ~$375M EV. Against ~$0.80 adj FY26 EPS that's ~23x adj P/E; against ~$79M revenue, ~4.7x EV/sales — a full price for a flat-growth biosimulation asset, above Certara's ~2.3x EV/sales.
• Spread: stock ~$16.37 pre-deal vs $18.50 → the arb spread is the (18.50 − current) ÷ current to a Q4-2026 close.
• Why it closes: board unanimous; founders' ~16% locked by voting agreement; all-cash (no financing-market risk of a stock deal); a credible healthcare PE sponsor (Altaris) with a clear strategic logic — merge SLP with portfolio co Chemical Computing Group (molecular design) to build a broader computational-drug-discovery platform. Antitrust risk is low (complementary, sub-scale software). The principal residual risks are a shareholder vote surprise (very unlikely with 16% pre-committed and a 26% premium) or a superior proposal (possible but no rival bidder has emerged).

Forecast logging: Skipped per --watchlist rules (no forecast.ts create in the breadth loop). The natural scoreable forecast here is binary — "SLP/Altaris merger closes by 2026-12-31, p≈0.90" — to be logged in /thesis if Connor takes a merger-arb position, not here.

Lens 12 · Bull vs Bear

Bull (standalone, the case Altaris is buying): A profitable, debt-free, cash-generative (~$18M OCF) biosimulation #2 with a regulatory-grade moat on GastroPlus/PBPK and a structural tailwind — the FDA's animal-testing roadmap names in silico PBPK as a sanctioned NAM, which over a decade should pull simulation into every preclinical package. Margins have recovered to 66% gross / 36% adj-EBITDA after the cost reset; backlog up ~18%. In private hands, combined with CCG, freed from quarterly-guidance scrutiny and the public market's biosimulation derate, it can be rebuilt into a broader platform. At $18.50 the buyer captures the cash flows plus the option on the NAM tailwind cheaply.

Bear (why the public market broke it — and the pre-mortem): Organic growth is flat-to-down and the flagship (GastroPlus) has plateaued (+1.2%); two service lines are shrinking double-digits; the entire "biosimulation rerates as AI-bio" thesis has failed in public markets (SLP −38%, Certara at ~2.3x sales guiding 0-4%). Management destroyed ~$76M of capital on Pro-ficiency and cut the dividend to fund it. Pre-mortem (the thesis that already broke): they bought training/comms (Pro-ficiency) at the top of the cycle expecting cross-sell synergy; the synergy didn't materialize, pharma budgets tightened, growth stalled, and the asset was impaired within a year — exactly what happened. Multiples: for a standalone public SLP, a growth multiple was never justified at flat organic growth; the stock was correctly de-rated. The contrarian point the market is now refusing to see is benign: with a signed all-cash deal at a 26% premium, the equity risk has collapsed to deal-completion risk — the fundamental bear case is now Altaris's problem, not the public shareholder's.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull — but the deal blunts most of it for the equity holder:

• Where revenue is concentrated / what breaks it: GastroPlus (~28% of revenue) is mature and flat; if the FDA NAM roadmap slows or pharma standardizes on Certara (the scaled leader with the "Non-Animal Navigator"), SLP's #2 position erodes. The growth engine is policy-dependent and competition-exposed.
• Why the moat is weaker than bulls think: validation lock-in protects the installed base but has not produced growth — flat GastroPlus is the proof. Services (42% of revenue) are commoditizing (GM collapsed, two lines shrinking).
• Most dangerous competitor bulls underrate: Certara — 5x the scale, same tailwind, arguably better-positioned in AI-enabled biosimulation; SLP risks being the perennial #2 that gets out-invested.
• Worst capital allocation: Pro-ficiency — a textbook top-of-cycle, synergy-assumed acquisition impaired ~72% within a year, funded partly by killing the dividend. That is the single most damning fact about this management team.
• Assumptions that must hold for $18.50: essentially just the deal closes. If you're short the standalone story you're right on the fundamentals but wrong on the trade — the all-cash floor at $18.50 caps your downside-capture; shorting into a signed take-private with 16% locked and board-unanimous is a low-reward, asymmetric-loss bet (deal-break is your only payoff, and it's ~10% probable).
• Single permanent-impairment scenario: for the business, a faster-than-expected shift of preclinical spend to a rival platform amid a multi-year pharma-R&D recession. Plausibility: real over 3-5 years — which is precisely why the board sold rather than fought, and why a PE buyer (patient capital, no quarterly tape) is the natural owner.

Lens 14 · Management Questions (ordered by information value)

Reframed for the live situation — the top questions are now deal- and board-process questions.

1. Why sell now, at $18.50, rather than execute the standalone turnaround? What did the board conclude about the standalone 3-year value that made a 26%-premium cash exit superior?
2. Was there a competitive sale process (how many bidders, was a market-check / go-shop included), or was this a negotiated single-buyer deal with Altaris?
3. What is the breakup fee / go-shop window, and what are the specific regulatory conditions to close in Q4-2026?
4. What were the standalone management projections shared with the board and Altaris (the ones that justify $18.50 as fair)?
5. On Pro-ficiency: what specifically failed — the cross-sell thesis, integration, or the underlying clinical-training market — and what did you learn about your M&A diligence?
6. Is GastroPlus's plateau (+1.2%) a mature-product ceiling, a competitive-share loss to Certara, or a temporary pharma-budget effect? What re-accelerates it?
7. Why are QSP/QST (−26%) and PBPK services (−14%) shrinking, and is that demand permanently migrating (in-housing, competitors, or AI substitution)?
8. How real is the FDA animal-testing roadmap as a bookings driver — quantify the pipeline you can attribute to NAM-driven demand, not just the press release.
9. Post-close, what is the integration logic with Chemical Computing Group, and where do the product lines overlap vs. complement?
10. What is the durable organic growth rate of the software business ex-acquisitions over the last three years?
11. How exposed is the cloud ecosystem to AWS single-sourcing, and is multi-cloud on the roadmap?
12. What is net revenue retention by product, and customer concentration in the top 10 accounts?
13. How do you defend pricing and validation lock-in against a 5x-larger Certara investing into the same tailwind?
14. What is the scientist-talent retention picture after the 10% RIF, and how dependent is the moat on specific key modelers?
15. If the deal breaks, what is the standalone capital-allocation plan — buybacks (the $30M authorization), bolt-ons, or reinstated dividend?

---